All In Biotech

Free tool

FAERS Monitor: Elzonris

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761116 or its brand name (Elzonris, Tagraxofusp-Erzs). Reports on generic versions are filed under their own applications.

Reports

538

Serious

459

85% of reports

Hospitalization

135

Death reported

161

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • capillary leak syndrome130
  • pyrexia47
  • off label use43
  • death41
  • disease progression38
  • thrombocytopenia35
  • blood albumin decreased29
  • drug ineffective28
  • weight increased28
  • tumour lysis syndrome27
  • hypoalbuminaemia25
  • acute kidney injury24
  • sepsis23
  • hypotension22
  • transaminases increased22

Reports by year received

View as table
YearReports
201958
202060
202175
202272
202387
202469
202563
202654

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,621 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
capillary leak syndromeSignal1302623.72244.3316,981
blood albumin decreasedSignal29143.4100.63,948
hypoalbuminaemiaSignal25126.286.02,972
tumour lysis syndromeSignal27120.383.33,069
transaminases increasedSignal2238.725.7771
disease progressionSignal3812.69.2395
thrombocytopeniaSignal3512.28.9352
sepsisSignal238.15.4136
acute kidney injurySignal246.14.199
pyrexiaSignal475.34.0163
weight increasedSignal284.93.484
hypotensionSignal224.32.853
off label use431.91.419
death411.91.416
drug ineffective280.80.61

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.